Effects of Chest Physiotherapy in Hyperventilation Syndrome (SHV)

August 30, 2023 updated by: Marc Beaumont, Centre Hospitalier des Pays de Morlaix

Effects of Chest Physiotherapy in Hyperventilation Syndrom : a Multicentric Observational Study

Hyperventilation syndrome induce dyspnea and altered quality of life. the aim of this study is to assess the impact of chest physiotherapy on hyperventilation syndrome' symptoms

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

46

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Morlaix, France, 29600
        • Beaumont

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

patients with hyperventilation syndrome adressed for chest physiotherapy

Description

Inclusion Criteria:

  • patients addressed for hyperventilation syndrome
  • patient aged 18 years or over
  • patient able to consent and having sign a consent form

Exclusion Criteria:

  • respiratory disease (COPD, interstitial lung disease, bronchiectasis, cystic fibrosis, uncontrolled asthma)
  • patient with an inability to complete questionaires
  • refusal of participation
  • patient under tutorship or curatorship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of Nijmegen score
Time Frame: 5 weeks
Nijmegen score is measured at baseline and after 5 weeks. The Nijmegen questionnaire allows to assess hyperventilation symptoms. the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.
5 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of Nijmegen Score
Time Frame: 1 week
Nijemegen score is measured at baseline and after 1 week. The Nijmegen questionnaire allows to assess hyperventilation symptoms the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.
1 week
change of Hospital Anxiety and Depression score (HAD)
Time Frame: 5 weeks
Anxiety and depression scores are measured at baseline and after 5 weeks. the minimum and maximum values are between 0 to 21 for each item (Anxiety and Depression), and higher scores mean a worse outcome.
5 weeks
change of Short Form-36 score (SF-36)
Time Frame: 5 weeks

SF 36 score is measured at baseline and after 5 weeks. SF36 allows to assess quality of life.

the minimum and maximum values are between 0 to 100, and higher scores mean a better outcome.
5 weeks
change of Dyspnea-12 score
Time Frame: 5 weeks

Dyspnea-12 is measured at at baseline and after 5 weeks.

Dyspnea-12 questionnaire allows to assess sensorial and emotional component of dyspnea. The minimum and maximum values are between à to 36, and higher scores mean a worse outcome.
5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier des Pays de Morlaix

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2021

Primary Completion (Actual)

August 1, 2023

Study Completion (Actual)

August 1, 2023

Study Registration Dates

First Submitted

May 27, 2022

First Submitted That Met QC Criteria

August 3, 2022

First Posted (Actual)

August 4, 2022

Study Record Updates

Last Update Posted (Actual)

August 31, 2023

Last Update Submitted That Met QC Criteria

August 30, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHPMorlaix
  • CEPRO 2021-028 (Registry Identifier: SPLF)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperventilation

Clinical Trials on chest physiotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe